Endometrial Cancer Clinical Trials
Here are the 6 most popular medical studies for endometrial cancer
mTOR inhibitor
Everolimus + Letrozole for Ovarian Cancer
This trial is testing if the combination of everolimus (Afinitor®) and letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or endometrial cancer.
Anti-diabetic drug
Metformin + LR-IUD for Endometrial Cancer
This trial is for women with biopsy-proven cancer or complex atypical hyperplasia who are not candidates for surgery, to see if adding metformin to standard levonorgestrel-releasing intrauterine device (LR-IUD) treatment helps.
mTOR inhibitor
Everolimus + Letrozole + Metformin for Endometrial Cancer
This trial will test if everolimus, letrozole, and metformin can help control endometrial cancer that has come back or is progressing. Researchers will also study if the combination is safe.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Popular filter options for endometrial cancer trials
Adenocarcinoma Clinical Trials
View 29 Adenocarcinoma medical studies.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug to see if it's safe and effective in cancer patients with a specific genetic mutation. Patients who have already tried the standard of care and couldn't tolerate it are eligible. The trial will last up to 2 years.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Topoisomerase I inhibitors
ELU001 for Ovarian and Endometrial Cancers
This trial is focused on subjects with advanced, recurrent or refractory FRα overexpressing tumors. ELU001 is a new chemical entity consisting of payloads and targeting moieties covalently bound by linkers to the C'Dot particle carrier. This is the first trial of its kind and a novel molecular entity.
Endometrioid Adenocarcinoma Clinical Trials
View 28 Endometrioid Adenocarcinoma medical studies.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug to see if it's safe and effective in cancer patients with a specific genetic mutation. Patients who have already tried the standard of care and couldn't tolerate it are eligible. The trial will last up to 2 years.
Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
Metastatic Endometrial Cancer Clinical Trials
View 96 metastatic endometrial cancer medical studies.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug to see if it's safe and effective in cancer patients with a specific genetic mutation. Patients who have already tried the standard of care and couldn't tolerate it are eligible. The trial will last up to 2 years.
Checkpoint Inhibitor
Pembrolizumab + Chemotherapy/Radiotherapy for Endometrial Cancer
This trial is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation improves disease-free survival and overall survival in patients with non-small cell lung cancer.
Phase 3 Endometrial Cancer Clinical Trials
View 96 phase 3 endometrial cancer medical studies.
Checkpoint Inhibitor
Pembrolizumab + Chemotherapy/Radiotherapy for Endometrial Cancer
This trial is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation improves disease-free survival and overall survival in patients with non-small cell lung cancer.
Monoclonal Antibodies
Pembrolizumab + Lenvatinib for Endometrial Cancer
This trial will compare the effectiveness of a new immunotherapy drug combination to chemotherapy for women with advanced endometrial cancer. The hypothesis is that the immunotherapy combo will be better than chemo in terms of progression-free survival and overall survival.
Monoclonal Antibodies
Immunotherapy vs Chemotherapy for Endometrial Cancer
This trial is testing whether the immunotherapy drug pembrolizumab is better than the standard chemotherapy treatment for women with endometrial cancer that is resistant to other treatments.
Endometrial Cancer Clinical Trials With No Placebo
View 96 endometrial cancer medical studies that do not have a placebo group.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug to see if it's safe and effective in cancer patients with a specific genetic mutation. Patients who have already tried the standard of care and couldn't tolerate it are eligible. The trial will last up to 2 years.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Monoclonal Antibodies
Pembrolizumab + Lenvatinib for Endometrial Cancer
This trial will compare the effectiveness of a new immunotherapy drug combination to chemotherapy for women with advanced endometrial cancer. The hypothesis is that the immunotherapy combo will be better than chemo in terms of progression-free survival and overall survival.
View More Endometrial Cancer Trials
See another 65 medical studies focused on endometrial cancer.
Frequently Asked Questions
Introduction to endometrial cancer
What are the top hospitals conducting endometrial cancer research?
Endometrial cancer, a type of cancer that affects the lining of the uterus, has seen significant advancements in research and treatment thanks to the efforts of top hospitals across the United States. New york's Memorial Sloan Kettering Cancer Center leads the way with an impressive 13 ongoing clinical trials dedicated to endometrial cancer. Over the years, they have conducted a total of 46 trials since their first recorded study in 2003. In Houston, M D Anderson Cancer Center is making strides as well, currently conducting 11 active endometrial cancer trials and having completed 37 studies thus far since initiating their initial trial in 2002.
Further contributing to this vital research is Massachusetts General Hospital in Boston with eight ongoing endometrial cancer trials and a history of seventeen past investigations dating back to their first recorded trial on this disease in 2005. Northwestern University in Chicago also plays a key role by conducting eight active clinical trials for endometrial cancer while having accomplished twenty-two previous studies since embarking on their inaugural trial in 2003.
Meanwhile, located at Washington University School of Medicine in St. Louis, researchers are working diligently on seven current endometrial cancer trials and have successfully completed thirty-six investigations throughout nearly three decades; theirs began all the way back when they recorded their very first trial concerning this condition backin1992.
These esteemed hospitals serve as beacons of hope for those affected by endometrial cancer - offering state-of-the-art care through cutting-edge clinical trials. By pushing boundaries and exploring new avenues for treatment options, these medical institutions are bringing us closer to breakthroughs that will improve outcomes for patients battling this complex disease nationwide
Which are the best cities for endometrial cancer clinical trials?
When it comes to endometrial cancer clinical trials, a few cities stand out as leading the way in research and development. Houston, Texas takes the lead with 51 active trials investigating treatments like Levonorgestrel-Releasing Intrauterine System, Metformin, and Lymph Node Mapping. New york, New York follows closely behind with 46 ongoing studies focused on innovative approaches such as LY3537982, Pembrolizumab, and Copanlisib. Boston, Massachusetts also plays a significant role with 33 active trials exploring options like Abemaciclib and Avelumab. These cities are at the forefront of endometrial cancer research, offering patients access to cutting-edge clinical trials that hold promise for improved treatments and outcomes.
Which are the top treatments for endometrial cancer being explored in clinical trials?
Endometrial cancer research is rapidly progressing with exciting developments in clinical trials. Leading the pack is pembrolizumab, a groundbreaking treatment currently being explored in eight active trials for endometrial cancer. Since its introduction in 2015, it has been involved in a total of 39 all-time clinical trials dedicated to combating this form of cancer. Close behind are niraparib and abemaciclib, both showing promise with three ongoing trials each and accumulating eight and six all-time endometrial cancer trials respectively since their first listings in 2017 and 2018. Also making strides is pembrolizumab, featuring prominently with two active trials and four all-time endometrial cancer studies since its debut alongside other promising treatments on the horizon.
What are the most recent clinical trials for endometrial cancer?
Exciting advancements in the field of endometrial cancer research offer hope for improved treatment options. Recent clinical trials have explored various approaches to combat this disease. NPX267, a Phase 1 trial, has shown promise as a potential treatment for endometrial cancer. Additionally, PRO1184 is being investigated in both Phase 1 and Phase 2 trials, with the aim of enhancing outcomes for patients with this condition. Another study focused on combining BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel to target endometrial cancer cells effectively. Furthermore, SGN-ALPV and copanlisib are also undergoing investigation as potential therapies in separate clinical trials for endometrial cancer management. These ongoing studies provide renewed optimism and hold great potential for future treatment strategies against endometrial cancer.
What endometrial cancer clinical trials were recently completed?
In the realm of endometrial cancer, several clinical trials have recently reached completion, bringing hope for improved treatment options. Among them, a trial sponsored by Byondis B.V., exploring the potential of SYD985, concluded in May 2020. Additionally, the Medical College of Wisconsin completed a trial studying Rucaparib in July 2019. Notably, Xencor Inc.'s XmAb®22841 trial wrapped up in May 2019 as well. These advancements signify significant progress and emphasize ongoing efforts to combat endometrial cancer and enhance patient outcomes.